Free Trial

Fulcrum Therapeutics (FULC) Short Interest Ratio & Short Volume

Fulcrum Therapeutics logo
$7.88 +0.04 (+0.51%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$7.73 -0.15 (-1.89%)
As of 07/16/2025 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fulcrum Therapeutics Short Interest Data

Fulcrum Therapeutics (FULC) has a short interest of 5.64 million shares, representing 11.24% of the float (the number of shares available for trading by the public). This marks a -3.09% decrease in short interest from the previous month. The short interest ratio (days to cover) is 9.2, indicating that it would take 9.2 days of the average trading volume of 905,546 shares to cover all short positions.

Current Short Interest
5,640,000 shares
Previous Short Interest
5,820,000 shares
Change Vs. Previous Month
-3.09%
Dollar Volume Sold Short
$38.80 million
Short Interest Ratio
9.2 Days to Cover
Last Record Date
June 30, 2025
Outstanding Shares
53,980,000 shares
Short Percent of Float
11.24%
Today's Trading Volume
305,372 shares
Average Trading Volume
905,546 shares
Today's Volume Vs. Average
34%
Short Selling Fulcrum Therapeutics?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Fulcrum Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

FULC Short Interest Over Time

FULC Days to Cover Over Time

FULC Percentage of Float Shorted Over Time

Fulcrum Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
6/30/20255,640,000 shares $38.80 million -3.1%11.2%9.2 $6.88
6/15/20255,820,000 shares $39.87 million +2.5%11.6%10.8 $6.85
5/31/20255,680,000 shares $38.96 million +15.2%11.0%10.2 $6.86
5/15/20254,930,000 shares $32.54 million +45.0%9.5%8.9 $6.60
4/30/20253,400,000 shares $13.09 million -4.5%N/A6.8 $3.85
4/15/20253,560,000 shares $10.82 million -4.6%6.9%8.9 $3.04
3/31/20253,730,000 shares $10.74 million -28.5%7.2%8.3 $2.88
3/15/20255,220,000 shares $16.29 million +6.1%10.1%8.3 $3.12
2/28/20254,920,000 shares $17.66 million +10.8%9.5%7.2 $3.59
2/15/20254,440,000 shares $16.38 million +2.5%8.6%6.1 $3.69
1/31/20254,330,000 shares $17.15 million -7.3%N/A5.2 $3.96
1/15/20254,670,000 shares $19.15 million +10.4%N/A5.4 $4.10
12/31/20244,230,000 shares $19.88 million -0.7%N/A4.8 $4.70
12/15/20244,260,000 shares $16.87 million -7.0%N/A4.1 $3.96
11/30/20244,580,000 shares $17.63 million -2.1%N/A2.7 $3.85
11/15/20244,680,000 shares $14.06 million -5.8%N/A2.8 $3.01
10/31/20244,970,000 shares $15.71 million -10.0%N/A3.1 $3.16
10/15/20245,520,000 shares $20.20 million -6.4%N/A3.3 $3.66
9/30/20245,900,000 shares $21.06 million -48.3%N/A3.5 $3.57
9/15/202411,400,000 shares $36.25 million +41.4%N/A6.8 $3.18
8/31/20248,060,000 shares $68.91 million -1.1%N/A8.7 $8.55
8/15/20248,150,000 shares $78.97 million +6.1%N/A9 $9.69
7/31/20247,680,000 shares $71.27 million +5.8%N/A8.8 $9.28
7/15/20247,260,000 shares $61.35 million +37.2%N/A9.3 $8.45
6/30/20245,290,000 shares $32.80 million +36.3%N/A7.2 $6.20
6/15/20243,880,000 shares $28.91 million +8.1%N/A6.8 $7.45
5/31/20243,590,000 shares $28.18 million +16.2%N/A6.7 $7.85
5/15/20243,090,000 shares $25.49 million +3.0%N/A5 $8.25
4/30/20243,000,000 shares $21.39 million +18.6%N/A5 $7.13
4/15/20242,530,000 shares $18.62 million +12.0%N/A4 $7.36
3/31/20242,260,000 shares $21.33 million -5.4%N/A3.4 $9.44
3/15/20242,390,000 shares $27.15 million -25.3%N/A3.4 $11.36
2/29/20243,200,000 shares $32.67 million -0.6%N/A4.5 $10.21
2/15/20243,220,000 shares $30.27 million -4.7%N/A5.1 $9.40
1/31/20243,380,000 shares $24.40 million -16.3%N/A5.5 $7.22
1/15/20244,040,000 shares $28.68 million +10.1%N/A6.7 $7.10
12/31/20233,670,000 shares $24.77 million +10.2%N/A6.5 $6.75
12/15/20233,330,000 shares $17.95 million -18.0%N/A6.2 $5.39
11/30/20234,060,000 shares $19.49 million +9.7%N/A7.8 $4.80
11/15/20233,700,000 shares $15.47 million -6.3%N/A6.1 $4.18
Is Elon's empire crumbling? (Ad)

The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.

Click here to see the Tesla shock that could blindside everyone.
10/31/20233,950,000 shares $14.38 million +1.0%N/A2 $3.64
10/15/20233,910,000 shares $15.21 million -2.7%N/A1.9 $3.89
9/30/20234,020,000 shares $17.85 million +7.5%N/A2 $4.44
9/15/20233,740,000 shares $16.79 million +5.1%N/A1.8 $4.49
8/31/20233,560,000 shares $19.69 million +30.4%N/A1.7 $5.53
8/15/20232,730,000 shares $11.55 million -22.2%N/A1.3 $4.23
7/31/20233,510,000 shares $13.41 million +0.3%N/A5 $3.82
7/15/20233,500,000 shares $12.88 million -4.1%N/A4.6 $3.68
6/30/20233,650,000 shares $12.05 million -19.3%N/A4.6 $3.30
6/15/20234,520,000 shares $13.74 million +9.4%N/A5.3 $3.04
5/31/20234,130,000 shares $11.23 million +4.8%N/A4.1 $2.72
5/15/20233,940,000 shares $14.34 million -17.6%N/A3.2 $3.64
4/30/20234,780,000 shares $11.95 million -6.6%N/A3.9 $2.50
4/15/20235,120,000 shares $12.34 million +3.6%N/A4.2 $2.41
3/31/20234,940,000 shares $14.08 million +25.1%N/A3.8 $2.85
3/15/20233,950,000 shares $15.01 million -2.5%N/A3.1 $3.80
2/28/20234,050,000 shares $24.46 million +7.7%N/A3.8 $6.04
2/15/20233,760,000 shares $48.69 million +6.2%N/A3.8 $12.95
1/31/20233,540,000 shares $44.64 million +6.6%N/A4.6 $12.61
1/15/20233,320,000 shares $45.48 million -7.3%N/A4.6 $13.70
12/30/20223,580,000 shares $26.06 million +21.0%N/A5.7 $7.28
12/15/20222,960,000 shares $16.22 million -9.2%N/A6.1 $5.48
11/30/20223,260,000 shares $22.33 million -4.4%N/A8.5 $6.85
11/15/20223,410,000 shares $24.48 million -2.0%N/A8.9 $7.18
10/31/20223,480,000 shares $19.35 million +0.6%N/A8 $5.56
10/15/20223,460,000 shares $25.95 million -3.9%N/A7.5 $7.50
9/30/20223,600,000 shares $29.12 million -7.2%N/A8.4 $8.09
9/15/20223,880,000 shares $35.31 million +13.8%N/A8.4 $9.10
8/31/20223,410,000 shares $25.23 million +5.3%N/A5.3 $7.40
8/15/20223,240,000 shares $25.34 million -8.2%N/A4.6 $7.82
7/31/20223,530,000 shares $20.76 million -6.1%12.0%4.8 $5.88
7/15/20223,760,000 shares $20.27 million +1.4%12.8%5.1 $5.39
6/30/20223,710,000 shares $18.18 million +6.6%12.6%4.3 $4.90
6/15/20223,480,000 shares $15.35 million -7.0%11.8%3.9 $4.41
5/31/20223,740,000 shares $26.63 million +9.4%12.7%5 $7.12
5/15/20223,420,000 shares $28.32 million -21.7%11.6%4.7 $8.28
4/30/20224,370,000 shares $42.04 million +63.1%15.1%6.4 $9.62
4/15/20222,680,000 shares $35.48 million -0.4%9.3%4.4 $13.24
3/31/20222,690,000 shares $63.62 million -5.0%9.3%5.4 $23.65
3/15/20222,830,000 shares $44.52 million +12.8%9.8%6.6 $15.73
2/28/20222,510,000 shares $27.61 million -4.9%8.4%6 $11.00
2/15/20222,640,000 shares $29.81 million +25.7%8.8%6.5 $11.29
1/31/20222,100,000 shares $25.54 million +17.3%7.2%4.7 $12.16
1/15/20221,790,000 shares $24.92 million -2.7%N/A0 $13.92
12/31/20211,840,000 shares $32.55 million +8.2%6.1%4.1 $17.69
12/15/20211,700,000 shares $28.56 million -18.7%5.6%3.4 $16.80
11/30/20212,090,000 shares $30.31 million -31.0%6.9%3.9 $14.50
11/15/20213,030,000 shares $54.12 million +47.1%10.0%5.5 $17.86
10/29/20212,060,000 shares $45.61 million -0.5%6.9%0.6 $22.14
10/15/20212,070,000 shares $53.82 million +0.5%6.8%0.6 $26.00
Is Elon's empire crumbling? (Ad)

The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.

Click here to see the Tesla shock that could blindside everyone.
9/30/20212,060,000 shares $58.11 million +21.2%6.7%0.6 $28.21
9/15/20211,700,000 shares $45.85 million +4.9%5.9%0.5 $26.97
8/31/20211,620,000 shares $48.11 million -35.5%6.2%0.5 $29.70
8/13/20212,510,000 shares $57.55 million +261.2%13.1%0.8 $22.93
7/30/2021695,000 shares $5.08 million -7.4%4.4%0.4 $7.31
7/15/2021750,400 shares $7.02 million -12.2%4.7%4.9 $9.36
6/30/2021855,000 shares $8.96 million +29.1%5.4%6 $10.48
6/15/2021662,500 shares $5.59 million -2.4%4.2%5.9 $8.44
5/28/2021678,600 shares $6.06 million -5.4%4.3%7.7 $8.93
5/14/2021717,100 shares $7.09 million -3.6%4.5%8 $9.89
4/30/2021743,500 shares $8.35 million -3.6%4.8%7.4 $11.23
4/15/2021771,100 shares $9.23 million +0.5%3.6%6.4 $11.97
3/31/2021767,600 shares $8.77 million +8.9%3.6%5.4 $11.43
3/15/2021705,000 shares $8.62 million +2.0%3.3%4.6 $12.22
2/26/2021691,000 shares $8.82 million -4.6%3.2%4.6 $12.77
2/12/2021724,100 shares $9.70 million +2.4%3.5%4.5 $13.40
1/29/2021707,500 shares $7.96 million -21.8%4.1%4.3 $11.25
1/15/2021904,800 shares $10.27 million -9.5%5.3%5.3 $11.35
12/31/20201,000,000 shares $12.69 million +13.2%6.8%6 $12.69
12/15/2020883,700 shares $11.80 million -5.1%6.0%4.7 $13.35
11/30/2020931,000 shares $10.74 million -9.6%6.3%4.6 $11.54
11/15/20201,030,000 shares $13.03 million -22.0%7.0%5.1 $12.65
10/30/20201,320,000 shares $13.11 million +9.1%9.7%5.5 $9.93
10/15/20201,210,000 shares $13.64 million +5.2%8.9%5 $11.27
9/30/20201,150,000 shares $9.12 million +34.6%8.5%5.4 $7.93
9/15/2020854,200 shares $6.65 million +14.7%6.3%4.3 $7.78
8/31/2020745,000 shares $5.42 million +91.8%5.5%4.2 $7.27
8/14/2020388,400 shares $2.96 million -22.2%2.9%2.5 $7.62
7/31/2020499,200 shares $7.92 million +6.1%3.6%4.4 $15.87

FULC Short Interest - Frequently Asked Questions

What is Fulcrum Therapeutics' current short interest?

Short interest is the volume of Fulcrum Therapeutics shares that have been sold short but have not yet been closed out or covered. As of June 30th, investors have sold 5,640,000 shares of FULC short. 11.24% of Fulcrum Therapeutics' shares are currently sold short. Learn More on Fulcrum Therapeutics' current short interest.

What is a good short interest ratio for Fulcrum Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. FULC shares currently have a short interest ratio of 9.0. Learn More on Fulcrum Therapeutics's short interest ratio.

Which institutional investors are shorting Fulcrum Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Fulcrum Therapeutics: Belvedere Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Fulcrum Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 11.24% of Fulcrum Therapeutics' floating shares are currently sold short.

Is Fulcrum Therapeutics' short interest increasing or decreasing?

Fulcrum Therapeutics saw a drop in short interest in the month of June. As of June 30th, there was short interest totaling 5,640,000 shares, a drop of 3.1% from the previous total of 5,820,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Fulcrum Therapeutics' short interest compare to its competitors?

11.24% of Fulcrum Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Fulcrum Therapeutics: Biohaven Ltd. (14.27%), Evotec AG (0.21%), 89BIO (11.13%), Janux Therapeutics, Inc. (20.71%), ANI Pharmaceuticals, Inc. (10.44%), Edgewise Therapeutics, Inc. (16.42%), Mesoblast Limited (2.44%), Travere Therapeutics, Inc. (0.00%), CureVac N.V. (0.93%), Structure Therapeutics Inc. Sponsored ADR (13.40%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks.

What does it mean to sell short Fulcrum Therapeutics stock?

Short selling FULC is an investing strategy that aims to generate trading profit from Fulcrum Therapeutics as its price is falling. FULC shares are trading up $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Fulcrum Therapeutics?

A short squeeze for Fulcrum Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of FULC, which in turn drives the price of the stock up even further.

How often is Fulcrum Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including FULC, twice per month. The most recent reporting period available is June, 30 2025.




This page (NASDAQ:FULC) was last updated on 7/17/2025 by MarketBeat.com Staff
From Our Partners